ReviewReviews in endocrine & metabolic disorders2019
PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art.
Review in Reviews in endocrine & metabolic disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic performance of 2-[Endocrine · 2025Pooled it
- Application of radiomics and machine learning to thyroid diseases in nuclear medicine: a systematic review.Reviews in endocrine & metabolic disorders · 2024Pooled it
- The dilemma ofEndocrine · 2021Pooled it
- The relationship between the diagnostic performance of dual-energy CT quantitative parameters in thyroid cancer, cervical lymph node metastasis and prognosis.BMC endocrine disorders · 2026Article
- Medium-Term Study Results of Ultrasound-Guided Radiofrequency Ablation for Thyroid Follicular Neoplasm With Low SUV in PET/CT.International journal of endocrinology · 2026Article
- The Role of Serum Thyroglobulin Doubling Time in Predicting Recurrences/Metastasis onNuclear medicine and molecular imaging · 2025Article
- Enhanced staging of differentiated thyroid carcinoma: integrating [European journal of nuclear medicine and molecular imaging · 2025Article
- Diagnostic value of deep learning of multimodal imaging of thyroid for TI-RADS category 3-5 classification.Endocrine · 2025Article
- Meta-Analysis on the Prevalence and Significance of Incidental Findings in the Thyroid Gland Using Other PET Radiopharmaceuticals Beyond [Pharmaceuticals (Basel, Switzerland) · 2025Review
- AI may help to predict thyroid nodule malignancy based on radiomics features from [EJNMMI research · 2025Article
- Assessing the Frequency of Deferrable Thyroid Nodule Biopsies to De-escalate Low-Value Care.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2024Article
- How [Cancers · 2024Article
- Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Personalized Diagnosis in Differentiated Thyroid Cancers by Molecular and Functional Imaging Biomarkers: Present and Future.Diagnostics (Basel, Switzerland) · 2022Review
- Updated clinical management guidance during the COVID-19 pandemic: thyroid nodules and cancer.European journal of endocrinology · 2022Review
- Radiomics analysis improvesEndocrine · 2022Article
- Risk-stratification of thyroid nodules examined byEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021Article
- Prognostic Role of 2-[Diagnostics (Basel, Switzerland) · 2021Article
- The role of Tg kinetics in predicting 2-[Endocrine · 2021Article
- Usefulness of PET/CT withDiagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A more conservative approach to the clinical management of thyroid nodules and differentiated thyroid cancer has recently been proposed by the 2015 ATA guidelines. In this context, fine-needle aspiration biopsy has been reserved for nodules with particular ultrasound features or dimensions that exclude low-risk thyroid lesions. Accordingly, a less aggressive surgical approach (i.e. lobectomy) has been recommended as the first-choice treatment in nodules with indeterminate cytology or in small cytologically confirmed malignant nodules. At the same time, radioactive remnant ablation has been considered only for DTC patients with concrete risks of disease persistence/relapse after thyroidectomy. In addition, further radioactive iodine therapies (RAI) have been proposed only for patients presenting unresectable and iodine-avid structural relapse. In this complex scenario, which requires attention to each clinical aspect of the patient, the introduction of accurate diagnostic tools is highly warranted. PET/CT is a very sensitive and specific diagnostic procedure that can better characterize the risk of thyroid nodules, identify DTC relapse early and predict the response to RAI. Thus, it seems essential to customize a more conservative approach to thyroid nodules and DTC patients. The aim of this review is to report the principal clinical context in which PET/CT has been used and to evaluate the evidence-based support for each diagnostic indication.
Indexed as
Identifiers
30900067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.